Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT02456207 | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 80 | Sinocelltech Ltd.INDUSTRY | 1 | May 28, 2015 | clinicaltrials |
| NCT00998049 |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant |
| completed |
| Phase 2 |
| 40 |
| Mayo ClinicOTHER |
| 1 |
| May 14, 2015 |
| clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 24, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | withdrawn | Phase 2 | 0 | Meir Medical CenterOTHER | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT02399189 | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 39 | Jun ZhuOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | withdrawn | Phase 2 | 0 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 6, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00210314 | Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00086203 | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | — | Point TherapeuticsINDUSTRY | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01521689 | Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment(LLCRlowdoz) | unknown | Phase 2 | 35 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00066638 | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00002849 | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 93 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 0 | Mar 6, 2015 | clinicaltrials |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT00832234 | Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia(BDR-WM) | completed | Phase 2 | 59 | European Myeloma Network B.V.NETWORK | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT01310101 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Brno University HospitalOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT00440583 | The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP | completed | Phase 2 | 15 | Mahidol UniversityOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jan 5, 2015 | clinicaltrials |
| NCT00220285 | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00833560 | A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | completed | Phase 2 | 401 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT02093910 | Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT01470456 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 50 | SanofiINDUSTRY | 3 | Nov 13, 2014 | clinicaltrials |
| NCT00891839 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | completed | Phase 2 | 45 | CephalonINDUSTRY | 2 | Nov 4, 2014 | clinicaltrials |
| NCT01068392 | Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) | completed | Phase 2 | 42 | Dong-A University HospitalOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00433537 | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00388193 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00564200 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning(MINIALO-VELCAD) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00869999 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | completed | Phase 2 | 26 | Massachusetts General HospitalOTHER | 1 | Oct 27, 2014 | clinicaltrials |
| NCT01465230 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 2 | Yale UniversityOTHER | 1 | Oct 23, 2014 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2015source: clinicaltrials